REVIEW
The impact of medical therapy on left ventricular strain: Current state and future perspectives
Egor Karev,
Sergey L. Verbilo,
Eduard G. Malev PhD,
Maria N. Prokudina MD, PhD,
Corresponding Author
Egor Karev
Federal State Budgetary Institution “V.A. Almazov National Medical Research Center” of the Ministry of Health of the Russian Federation, Saint Petersburg, Russia
Correspondence
Egor Karev, Federal State Budgetary Institution “V.A. Almazov National Medical Research Center” of the Ministry of Health of the Russian Federation, 2 Akkuratova Street, Saint Petersburg 197341, Russia.
Email: [email protected]
Search for more papers by this authorSergey L. Verbilo
Federal State Budgetary Institution “V.A. Almazov National Medical Research Center” of the Ministry of Health of the Russian Federation, Saint Petersburg, Russia
Search for more papers by this authorEduard G. Malev PhD
Research Laboratory for Connective Tissue Dysplasia, Heart and Vessels Institute, Federal State Budgetary Institution “V.A. Almazov National Medical Research Center” of the Ministry of Health of the Russian Federation, Saint Petersburg, Russia
Search for more papers by this authorMaria N. Prokudina MD, PhD
Limited Liability Company “International Heart Center”, 6 Tverskaya street, Saint-Petersburg, 191015 Russia
Search for more papers by this authorEgor Karev,
Sergey L. Verbilo,
Eduard G. Malev PhD,
Maria N. Prokudina MD, PhD,
Corresponding Author
Egor Karev
Federal State Budgetary Institution “V.A. Almazov National Medical Research Center” of the Ministry of Health of the Russian Federation, Saint Petersburg, Russia
Correspondence
Egor Karev, Federal State Budgetary Institution “V.A. Almazov National Medical Research Center” of the Ministry of Health of the Russian Federation, 2 Akkuratova Street, Saint Petersburg 197341, Russia.
Email: [email protected]
Search for more papers by this authorSergey L. Verbilo
Federal State Budgetary Institution “V.A. Almazov National Medical Research Center” of the Ministry of Health of the Russian Federation, Saint Petersburg, Russia
Search for more papers by this authorEduard G. Malev PhD
Research Laboratory for Connective Tissue Dysplasia, Heart and Vessels Institute, Federal State Budgetary Institution “V.A. Almazov National Medical Research Center” of the Ministry of Health of the Russian Federation, Saint Petersburg, Russia
Search for more papers by this authorMaria N. Prokudina MD, PhD
Limited Liability Company “International Heart Center”, 6 Tverskaya street, Saint-Petersburg, 191015 Russia
Search for more papers by this authorAbstract
The speckle tracking strain is becoming a frequently used marker of subclinical left ventricular systolic dysfunction. Despite the wide range of data concerning left ventricular strain variability in the general population and its changes in various pathologic conditions, the information about the impact of medical therapy on left ventricle strain is limited. This article provides an analysis of published studies of left ventricle strain changes in response to different agents and combinations of medical therapies used for hypertension and congestive heart failure.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
Open Research
DATA AVAILABILITY STATEMENT
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
REFERENCES
- 1Hensel KO, Jenke A, Leischik R. Speckle-tracking and tissue-Doppler stress echocardiography in arterial hypertension: a sensitive tool for detection of subclinical LV impairment. Biomed Res Int 2014; 2014:472562, 1–9.
- 2Smiseth OA, Torp H, Opdahl A, Haugaa KH, Urheim S. Myocardial strain imaging: how useful is it in clinical decision making? Eur Heart J. 2016; 37(15): 1196-1207. doi:10.1093/eurheartj/ehv529
- 3Reant P, Zaroui A, Donal E, et al. Identification and characterization of super-responders after cardiac resynchronization therapy. Am J Cardiol. 2010; 105(9): 1327-1335. doi:10.1016/j.amjcard.2009.12.058
- 4Collier P, Phelan D, Klein A. A test in context: myocardial strain measured by speckle-tracking echocardiography. J Am Coll Cardiol. 2017; 69(8): 1043-1056.
- 5Donal E, Bergerot C, Thibault H, et al. Influence of afterload on left ventricular radial and longitudinal systolic functions: a two-dimensional strain imaging study. Eur J Echocardiogr. 2009; 10(8): 914-921. doi:10.1093/ejechocard/jep095
- 6Rhea IB, Rehman S, Jarori U, Choudhry MW, Feigenbaum H, Sawada SG. Prognostic utility of blood pressure-adjusted global and basal systolic longitudinal strain. Echo Res Pract. 2016; 3(1): 17-24. doi:10.1530/ERP-15-0037
- 7Delgado V, Tops LF, van Bommel RJ, et al. Strain analysis in patients with severe aortic stenosis and preserved left ejection fraction undergoing surgical valve replacement. Eur Heart J. 2009; 30(24): 3037-3047. doi:10.1093/eurheartj/ehp351
- 8Tadic M, Cuspidi C, Pencic B, et al. The impact of arterial hypertension on left ventricular strain in patients with aortic stenosis and preserved ejection fraction. J Hypertens. 2019 Apr; 37(4): 747-753. doi:10.1097/HJH.0000000000001963
- 9Kosmala W, Przewlocka-Kosmala M, Sharman JE, Schultz MG, Marwick TH. Stability of left ventricular longitudinal and circumferential deformation over time and standard loading conditions. Eur Heart J Cardiovasc Imaging. 2017; 18(9): 1001-1007. doi:10.1093/ehjci/jew135
- 10Tadic M, Cuspidi C. The Effect of antihypertensive therapy on left ventricular longitudinal strain: missing part of the puzzle. J Cardiovasc Transl Res. 2020; 14: 125-128. doi:10.1007/s12265-020-09970-x
- 11Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018; 39(33): 3021-3104.
- 12Saito M, Khan F, Stoklosa T, Iannaccone A, Negishi K, Marwick TH. Prognostic implications of LV strain risk score in asymptomatic patients with hypertensive heart disease. JACC Cardiovasc Imaging. 2016; 9(8): 911-921.
- 13Yu B, Li I, Cornish B, et al. Relationship between global longitudinal strain and left ventricular diastolic function. JACC. 2019; 73(9) Supplement 1: 1675.
- 14Tadic M, Sala C, Carugo S, Mancia G, Grassi G, Cuspidi C. Myocardial strain in hypertension: a meta-analysis of two-dimensional speckle tracking echocardiographic studies. J Hypertens. 2021; 39(10): 2103-2112. doi:10.1097/HJH.0000000000002898
- 15Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. JHypertens. 2016; 34: 1921-1932.
- 16Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens. 2005; 23(12): 2113-2118.
- 17Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens. 2008; 26(7): 1282-1289.
- 18Kronish IM, Woodward M, Sergie Z, Ogedegbe G, Falzon L, Mann DM. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011; 123(15): 1611-1621.
- 19Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs – overview and meta-analyses. J Hypertens. 2015; 33(7): 1321-1341.
- 20Tadic M, Gherbesi E, Sala C, Carugo S, Cuspidi C. Effect of long-term antihypertensive therapy on myocardial strain: a meta-analysis. J Hypertens. 2022; 40(4): 641-647. doi:10.1097/HJH.0000000000003079
- 21Uziębło-Życzkowska B, Krzesiński P, Gielerak G, Skrobowski A. Speckle tracking echocardiography and tissue Doppler imaging reveal beneficial effect of pharmacotherapy in hypertensives with asymptomatic left ventricular dysfunction. J Am Soc Hypertens. 2017; 11(6): 334-342.
- 22Tzortzis S, Ikonomidis I, Triantafyllidi H, et al. Optimal blood pressure control improves left ventricular torsional deformation and vascular function in newly diagnosed Hypertensives: a 3-year follow-up Study. J Cardiovasc Transl Res. 2020; 13: 814-825. doi:10.1007/s12265-019-09951-9
- 23Ostroumova OD, Kochetkov AI, Lopukhina MV. Comparative analysis of the efficacy of fixed-dose combinations of amlodipine / Lisinopril and Bisoprolol / Hydrochlorthiazide in patients with essential arterial hypertension combined with obesity and overweight. Rat Pharmacother Cardiol. 2017; 13(4): 443-453. In Russian.
- 24Mizuguchi Y, Oishi Y, Miyoshi H, et al. Possible mechanisms of left ventricular torsion evaluated by cardioreparative effects of telmisartan in patients with hypertension. Eur J Echocardiogr: J Work Group Echocardiogr Eur Soc Cardiol. 2010; 11(8): 690-697.
- 25Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens (Greenwich). 2011; 13(9): 687-689.
- 26Bonow RO, Rosing DR, Epstein SE. The acute and chronic effects of verapamil on left ventricular function in patients with hypertrophic cardiomyopathy. Eur Heart J. 1983; 4(suppl_F): 57-65.
- 27Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The adverse experience committee and the multicenter diltiazem Postinfarction research Group. Circulation. 1991; 83: 52-6025.
- 28Packer M, O'Connor CM, Ghali JK, et al. Prospective randomized amlodipine survival evaluation study group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996; 335: 1107-1114.
- 29Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-heart failure trial (V-HeFT) Study Group. Circulation. 1997; 96: 856-863.
- 30Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990; 82(6): 1954-1961.
- 31Udelson JE, DeAbate CA, Berk M, et al. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. Am Heart J. 2000; 139(3): 503-510.
- 32Zusman RM, Christensen DM, Higgins J, Boucher CA. Nifedipine improves left ventricular function in patients with hypertension. J Cardiovasc Pharmacol. 1991; 18(6): 843-848.
- 33Klein HO, Ninio R, Oren V, et al. The acute hemodynamic effects of intravenous verapamil in coronary artery disease. Assessment of equilibrium-gated radio nuclide ventriculography. Circulation. 1983; 67: 101-110.
- 34Przyklenk K, KJoner RA. Effect of verapamil on post ischemic 'stunned' myocardium: importance of the timing of treatment. J Am Coll Cardiol. 1988; 11: 614-623.
- 35van der Wall EE, Niemieyer MG, Vliegen HW, et al. Improvement of left ventricular function in silent ischemia following myocardial infarction, after administration of diltiazem. J Cardiovasc Pharmacol. 1991; 18(Suppl 9): S68-S72.
- 36Motoki H, Koyama J, Izawa A, et al. Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy. Echocardiography. 2014; 31(10): 1230-1238.
- 37Morris DA, Ma XX, Belyavskiy E, et al. Left ventricular longitudinal systolic function analysed by 2D speckle-tracking echocardiography in heart failure with preserved ejection fraction: a meta-analysis. Open Heart. 2017; 4(2):e000630. doi:10.1136/openhrt-2017-000630
- 38Bshiebish HAH, Al-Musawi AH, Khudeir SA. Role of global longitudinal strain in assessment of left ventricular systolic function in patients with heart failure with preserved ejection fraction. J Saudi Heart Assoc. 2019; 31(2): 100-105. doi:10.1016/j.jsha.2018.12.002
- 39Sengeløv M, Jørgensen PG, Jensen JS, et al. Global longitudinal strain is a superior predictor of all-cause mortality in heart failure with reduced ejection fraction. JACC Cardiovasc Imaging. 2015; 8(12): 1351-1359. doi:10.1016/j.jcmg.2015.07.013], 10.1016/j.jcmg.2015.07.013]
- 40Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart. 2014; 100(21): 1673-1680. doi:10.1136/heartjnl-2014-305538
- 41D'Andrea A, Ilardi F, D'Ascenzi F, et al. Working Group of Echocardiography of the Italian Society of Cardiology (SIC). Impaired myocardial work efficiency in heart failure with preserved ejection fraction. Eur heart J Cardiovasc. Imaging. 2021; 22(11): 1312-1320. doi:10.1093/ehjci/jeab153
10.1093/ehjci/jeab153 Google Scholar
- 42Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the heart failure association (HFA) of the ESC [published correction appears in Eur heart J. 2016 Dec 30]. Eur Heart J. 2016; 37(27): 2129-2200.
- 43Ishizu T, Seo Y, Namekawa M, Murakoshi N, Ieda M, Kawakami Y. Left ventricular longitudinal strain as a marker for point of no return in hypertensive heart failure treatment. J Am Soc Echocardiogr. 2020; 33(2): 226-233.e1.
- 44Cheng S, Shah AM, Albisu JP, et al. Reversibility of left ventricular mechanical dysfunction in patients with hypertensive heart disease. J Hypertens. 2014; 32(12): 2479-2486.
- 45Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group JAMA. 2000; 283(10): 1295-1302.
- 46Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002; 106(17): 2194-2199.
- 47The cardiac insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353(9146): 9-13.
- 48Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005; 26(3): 215-225.
- 49Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 1995; 25(5): 1154-1161.
- 50Agrios JA, Kaladaridou AK, Skaltsiotes ES, et al. The effect of esmolol on left ventricular haemodynamic, rotational mechanics and strain in intact and infracted myocardium. Experimental study. Eur Heart J. 2013; 34(suppl_1): 463.
10.1093/eurheartj/eht307.P463 Google Scholar
- 51Jondeau G, Neuder Y, Eicher JC, et al. B-CONVINCED: Beta-blocker CONtinuation vs. INterruption in patients with congestive heart failure hospitalizED for a decompensation episode. Eur Heart J. 2009; 30(18): 2186-2192.
- 52Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers in heart failure collaborative Group, Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018; 39(1): 26-35.
- 53von Lueder TG, Kotecha D, Atar D, et al. Neurohormonal blockade in heart failure. Card Fail Rev. 2017; 3(1): 19-24.
- 54Weidemann F, Jamal F, Sutherland GR, et al. Myocardial function defined by strain rate and strain during alterations in inotropic states and heart rate. Am J Physiol Heart Circ Physiol. 2002; 283(2): H792-H799.
- 55Sardana M, Syed AA, Hashmath Z, et al. Beta-blocker use is associated with impaired left atrial function in hypertension. J Am Heart Assoc. 2017; 6(2):e005163.
- 56Palmieri V, Russo C, Palmieri EA, Pezzullo S, Celentano A. Changes in components of left ventricular mechanics under selective beta-1 blockade: insight from traditional and new technologies in echocardiography. Eur J Echocardiogr. 2009; 10(6): 745-752.
- 57Park JJ, Choi HM, Hwang IC, Park JB, Park JH, Cho GY. Myocardial strain for identification of β-blocker responders in heart failure with preserved ejection fraction. J Am Soc Echocardiogr. 2019; 32(11): 1462-1469.e8.
- 58Xu X, Wang DW. The progress and controversial of the use of beta blockers in patients with heart failure with a preserved ejection fraction. Int J Cardiol Heart Vasc. 2019; 26:100451.
- 59Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation Study investigators. N Engl J Med. 1999; 341(10): 709-717.
- 60Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published correction appears in N Engl J med. 2003 may 29;348(22):2271]. N Engl J Med. 2003; 348(14): 1309-1321.
- 61Zannad F, Gattis Stough W, Rossignol P, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012; 33(22): 2782-2795.
- 62Suzuki G, Morita H, Mishima T, et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation. 2002; 106(23): 2967-2972.
- 63Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, Marwick TH. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. Heart. 2013; 99(5): 320-326. doi:10.1136/heartjnl-2012-303329
- 64Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003; 107(20): 2559-2565.
- 65Udelson JE, Feldman AM, Greenberg B, et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail. 2010; 3(3): 347-353.
- 66Leader CJ, Moharram M, Coffey S, Sammut IA, Wilkins GW, Walker RJ. Myocardial global longitudinal strain: an early indicator of cardiac interstitial fibrosis modified by spironolactone, in a unique hypertensive rat model. PLoS One. 2019; 14(8):e0220837.
- 67Hare JL, Sharman JE, Leano R, Jenkins C, Wright L, Marwick TH. Impact of spironolactone on vascular, myocardial, and functional parameters in untreated patients with a hypertensive response to exercise. Am J Hypertens. 2013; 26(5): 691-699.
- 68Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation. 2004; 110(5): 558-565.
- 69Przewlocka-Kosmala M, Marwick TH, Mysiak A, Kosowski W, Kosmala W. Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction. Eur Heart J – Cardiovasc Imaging. 2019; 20(10): 1138-1146.
- 70Rujic D, Madsen PL, Pareek M, et al. Spironolactone improves left ventricular longitudinal strain and E/e’ in patients with atrial fibrillation and preserved ejection fraction: results from a randomized, double-blind. Placebo-Controlled Trial (INSPIRE-AF) Circulation. 2019; 140:A17126.
- 71Shah AM, Claggett B, Sweitzer NK, et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation. 2015; 132(5): 402-414.
- 72Raman SV, Hor KN, Mazur W, et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015; 14(2): 153-161.
- 73Grune J, Beyhoff N, Smeir E, et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for Finerenone's Antifibrotic activity. Hypertension. 2018 Apr; 71(4): 599-608. doi:10.1161/HYPERTENSIONAHA.117.10360
- 74Lowe J, Kolkhof P, Haupt MJ, et al. Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy. ESC Heart Fail. 2020; 7(6): 3983-3995. doi:10.1002/ehf2.12996
- 75Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117-2128. doi:10.1056/nejmoa1504720
- 76Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(4): 347-357. doi:10.1056/nejmoa1812389
- 77McDonagh TA, Metra M, Adamo M, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599-3726.
- 78Quagliariello V, De Laurentiis M, Rea D, et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol. 2021; 20(1): 150. doi:10.1186/s12933-021-01346-y
- 79Gamaza-Chulián S, Díaz-Retamino E, González-Testón F, et al. Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study. BMC Cardiovasc Disord. 2021; 21: 456. doi:10.1186/s12872-021-02250-9
- 80Tanaka H, Soga F, Tatsumi K, et al. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure. Cardiovasc Diabetol. 2020; 19(1): 6. doi:10.1186/s12933-019-0985-z
- 81Donal E, Coquerel N, Bodi S, et al. Importance of ventricular longitudinal function in chronic heart failure. Eur J Echocardiogr. 2011 Aug; 12(8): 619-627. doi:10.1093/ejechocard/jer089
- 82Karlsen S, Dahlslett T, Grenne B, et al. Global longitudinal strain is a more reproducible measure of left ventricular function than ejection fraction regardless of echocardiographic training. Cardiovasc Ultrasound. 2019; 17(1): 18. doi:10.1186/s12947-019-0168-9
- 83Bakhsh A, Thanassoulis G, Engert JC, Elstein E, Huynh T, Giannetti N. Withdrawal of beta- blockers and ACE inhibitors after left ventricular systolic function recovery in patient with dilated cardiomyopathy randomized control trial. Eur Heart J. 2020; 41(Issue Supplement_1: i86.
- 84Wong M, Staszewsky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol. 2002; 40(5): 970-975.
- 85Amorim S, Rodrigues J, Campelo M, et al. Left ventricular reverse remodeling in dilated cardiomyopathy- maintained subclinical myocardial systolic and diastolic dysfunction. Int J Cardiovasc Imaging. 2017; 33(5): 605-613.
- 86Dostal DE, Rothblum KC, Chermin MI, et al. Intracardiac detection of angiotensinogen and renin: evidence for a localized renin-angiotensin system in neonatal rat heart. Am J Physiol. 1992; 263: C828-C850.
- 87Ziang J, Linz W, Becker H, et al. Effects of converting enzyme inhibitors ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated rat heart. Eur J Pharmacol. 1984; 113: 215-223.
- 88Busatto V.C.W., Cicilini M.A., Mill J.G. Increased angiotensin-converting enzyme activity in the left ventricle after infarction Braz J Med Biol Res, May 1997; 30(5) 679–687
- 89De Vecchis R, Paccone A, Di Maio M. Sacubitril/valsartan therapy for 14 months induces a marked improvement of global longitudinal strain in patients with chronic heart failure: a retrospective cohort Study. Cardiol Res. 2019; 10(5): 293-302.
- 90Lee MMY, Brooksbank KJM, Wetherall K, et al. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). Circulation. 2021; 143(6): 516–525. doi: 10.1161/CIRCULATIONAHA.120.052186
- 91Larsen AH, Jessen N, Nørrelund H, et al. A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes. Eur J Heart Fail. 2020 Sep; 22(9): 1628-1637. doi:10.1002/ejhf.1656
- 92Halabi A, Yang H, Wright L, et al. Evolution of myocardial dysfunction in asymptomatic patients at risk of heart failure. JACC Cardiovasc Imaging. 2021; 14(2): 350-361. doi:10.1016/j.jcmg.2020.09.032
- 93O'Connor DM, Smith RS, Piras BA, et al. Heart rate reduction with Ivabradine protects against left ventricular remodeling by attenuating infarct expansion and preserving remote-zone contractile function and synchrony in a mouse model of Reperfused myocardial infarction. J Am Heart Assoc. 2016; 5(4):e002989. doi:10.1161/JAHA.115.002989
- 94Harada Y, Shimada K, Kubota Y, Yoshimoto T. Ivabradine for chemotherapy-related cardiac dysfunction in breast cancer. Cureus. 2021; 13(10):e18731. doi:10.7759/cureus.18731
- 95Boonhoh W, Kijtawornrat A, Sawangkoon S. Comparative effects of amiodarone and dronedarone treatments on cardiac function in a rabbit model. Vet World. 2019; 12(2): 345-351. doi:10.14202/vetworld.2019.345-351
- 96Ansari-Ramandi MM, Maleki M, Alizadehasl A, et al. Safety and effect of high dose allopurinol in patients with severe left ventricular systolic dysfunction. J Cardiovasc Thorac Res. 2017; 9(2): 102-107. doi:10.15171/jcvtr.2017.17
- 97Voors AA, Tamby JF, Cleland JG. Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. Eur J Heart Fail. 2020; 2(9): 1649-1658. doi:10.1002/ejhf.1933
- 98Michelsen MM, Rask AB, Suhrs E, Raft KF, Høst N, Prescott E Effect of ACE-inhibition on coronary microvascular function and symptoms in normotensive women with microvascular angina: a randomized placebo-controlled trial. PLoS One 2018;8; 13(6), e0196962
- 99Bansal M, Chan J, Leano R, Pillans P, Horowitz J, Marwick TH. Effects of perhexiline on myocardial deformation in patients with ischaemic left ventricular dysfunction. Int J Cardiol. 2010; 139(2): 107-112. doi:10.1016/j.ijcard.2009.08.007
- 100Auscher S, Moeller J, Loegstrup B, Egstrup K. Early intensive treatment with statins improves regional longitudinal systolic strain in patients with acute myocardial infarction. Eur. Heart J. 2013; 34(suppl_1):2714. 10.1093/eurheartj/eht309.2714
10.1093/eurheartj/eht309.2714 Google Scholar
- 101Oh K, Mustehsan MH, Patel SR, et al. Intensified statin preserves global longitudinal strain in transplanted heart. J. Heart Lung Transplant. 2020; 39(4) Supplement: s253. doi:10.1016/j/healun.2020.01.548
